1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,300 | 6,550 | 29.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | WUXI XDC (02268): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | 1 | HKEx | ||
| Fr | WUXI XDC (02268): ANNUAL REPORT 2025 | - | HKEx | ||
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| 09.04. | Akari Therapeutics Plc: Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDC | 1 | GlobeNewswire (USA) | ||
| 08.04. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 08.04. | WUXI XDC (02268): GRANT OF RESTRICTED SHARES UNDER THE 2024 SHARE SCHEME | 1 | HKEx | ||
| 06.04. | Akari Therapeutics slides 21% despite WuXi XDC backing its drug program | 3 | Seeking Alpha | ||
| 06.04. | Akari Therapeutics Partners with WuXi XDC to Accelerate Development of Novel PH1 Payload | 1 | Contract Pharma | ||
| 06.04. | Akari Therapeutics partners with WuXi XDC on ADC development | 2 | Investing.com | ||
| 06.04. | Akari Therapeutics Plc: Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing | 119 | GlobeNewswire (Europe) | TAMPA, Fla. and LONDON, April 06, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing... ► Artikel lesen | |
| 31.03. | WUXI XDC (02268): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ALL ... | 2 | HKEx | ||
| 23.03. | WUXI XDC (02268): INSIDE INFORMATION 2025 ANNUAL RESULTS PRESENTATION | - | HKEx | ||
| 23.03. | WUXI XDC (02268): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 13.03. | WUXI XDC (02268): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ALL ... | 8 | HKEx | ||
| 27.02. | WuXi XDC, Earendil Labs Partner to Accelerate the Development of ADCs | 1 | Contract Pharma | ||
| 27.02. | Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs | 2 | FierceBiotech | ||
| 27.02. | WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform | 369 | PR Newswire | SHANGHAI, Feb. 27, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization)... ► Artikel lesen | |
| 11.02. | WUXI XDC (02268): MAJOR TRANSACTION IN RELATION TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE ... | - | HKEx | ||
| 11.02. | WUXI XDC (02268): JOINT ANNOUNCEMENT DESPATCH OF COMPOSITE DOCUMENT RELATING TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED ... | 1 | HKEx | ||
| 11.02. | WUXI XDC (02268): PINK FORM OF OPTION OFFER ACCEPTANCE AND CANCELLATION OF SHARE OPTIONS GRANTED BY BIODLINK INTERNATIONAL COMPANY LIMITED | 1 | HKEx | ||
| 11.02. | WUXI XDC (02268): WHITE FORM OF SHARE OFFER ACCEPTANCE AND TRANSFER OF ORDINARY SHARE(S) IN THE ISSUED SHARE CAPITAL OF BIODLINK INTERNATIONAL COMPANY ... | 3 | HKEx |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,510 | -2,11 % | Prognoseschock bei Diagnostikspezialist sorgt für neue Unsicherheit: QIAGEN-Aktie unter Druck: Gewinnwarnung schürt Zweifel an Erholung | QIAGEN überrascht den Markt mit einer deutlichen Senkung der Jahresprognose für 2026. Die schwächelnde Nachfrage und zunehmende Unsicherheiten setzen den Diagnostikkonzern spürbar unter Druck.Gedämpfte... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,060 | 0,00 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| ERASCA | 9,080 | 0,00 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| EVOTEC | 5,005 | -2,63 % | Evotec-Aktie vor Schicksalszone: Durchbruch oder Absturz? | © Foto: fn SymbolbildEvotec hat zuletzt für Aufsehen gesorgt. Innerhalb weniger Wochen kletterte die Aktie um fast 50 Prozent nach oben, doch jetzt nähert sie sich einer Marke, die über vieles entscheiden... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 41,350 | 0,00 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| BIONTECH | 87,00 | 0,00 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,390 | 0,00 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study | ||
| ADMA BIOLOGICS | 10,600 | -2,75 % | Summers Value Fund adds TBPH, exits ADMA among Q1 moves | ||
| APOGEE THERAPEUTICS | 82,03 | -3,79 % | Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters | ||
| COGENT BIOSCIENCES | 35,880 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| IMMUNOVANT | 26,950 | 0,00 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,810 | -2,12 % | Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth | ||
| KINIKSA PHARMACEUTICALS | 53,00 | -1,58 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| DESIGN THERAPEUTICS | 15,780 | +23,18 % | Design Therapeutics, Inc.: Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates | Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,415 | -4,10 % | Dyne Therapeutics vor Quartalszahlen: Markteinführung von DMD-Therapie im Fokus |
WUXI XDC CAYMAN INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 6,300 Euro und damit -0,79 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WUXI XDC CAYMAN INC finden Sie auf Wallstreet Online.